Three-dimensional ultrasonic gait analysis in schizophrenic patients: Differences between conventional neuroleptic treatment and treatment with olanzapine;Dreidimensionale ultraschallgestützte ganganalyse bei schizophrenen patienten: Vergleich zwischen konventionellen neuroleptika und olanzapin

Psychiatrische Praxis, Supplement

Volumn 30, Issue 2, 2003, Pages

  Putzhammer, Albert ^a   Heindl, Bernhard ^a   Müller, Jürgen ^a   Broll, Karin ^a   Pfeiff, Liane ^a   Perfahl, Maria ^a   Hess, Linda ^a   Koch, Horst ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; AGED; CLINICAL ARTICLE; CONFERENCE PAPER; ECHOGRAPHY; FEMALE; GAIT; GAIT DISORDER; HUMAN; KINEMATICS; LOCOMOTION; MALE; RELIABILITY; SCHIZOPHRENIA; SPATIAL ORIENTATION; STATISTICAL SIGNIFICANCE; THREE DIMENSIONAL IMAGING; VELOCITY;

EID: 0038451512     PISSN: 16118332     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. McCreadie RG, Hall DJ, Berry IJ, Robertson LJ, Ewing JI, Geals MF. The Nithsdale schizophrenia surveys. X: Obstetric complications, family history and abnormal movements. Br J Psychiatry 1992; 160: 799-805
2. Whitworth AB, Fleischhacker WW. Adverse effects of antipsychotic drugs. Int Clin Psychopharmacol 1995: 9, Suppl 5: 21-27
3. Moeller H. Aktuelle Bewertung neuer/atypischer Neuroleptika. Nervenarzt 2000; 71: 329-344
4. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients (published erratum appears in J Clin Psychopharmacol 1993 Apr; 13 [2]: 149) (see comments). J Clin Psychopharmacol 1993; 13: 25-40
5. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19
6. Obens T. Gait analysis and plantar pressure distribution measurement. Orthopädie-Technik 2000; 9: 798-806
7. Vogt L, Banzer W. Measurement of lumbar spine kinematics in incline treadmill walking. Gait Posture 1999; 9: 18-23
8. Vogt L, Pfeifer K, Banzer W. Application of modern methods of movement analysis for functional diagnosis and risk screening of the athlete. Sportverletz Sportschaden 2001; 15: M33-M36
9. Messsystem zur 3D-Bewegungsanalyse CMS 70 P: Technische Anleitung mit Prüfberichten. 2000
10. Putzhammer A. Three-dimensional ultrasonic gait analysis in schizophrenic patients: treatment with conventional neuroleptics versus treatment with olanzapine. Pharmacopsychiatry 2002; 34: 194-200
11. Neumann D, Vogt L, Banzer W, Schreiber U. Kinematic and neuromuscular changes of the gait pattern after Achilles tendon rupture. Foot Ankle Int 1997; 18: 339-341
12. Portscher M, Vogt L, Pfeifer K, Banzer W. Reproducibility of lumbar spine kinematics in clinical gait analysis. Sportverletz Sportschaden 2000; 14: 50-54
13. Vogt L, Banzer W. Measurement of lumbar spine kinematics in incline treadmill walking. Gait Posture 1999; 9: 18-23
14. Beasley CM jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial (see comments). Neuropsychopharmacology 1996; 14: 111-123
15. Masand PS, Berry SL. Switching antipsychotic therapies. Ann Pharmacother Febr 2000; 34: 200-207
16. Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, Martin T, Litvinjuk Y, Giladi N. Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 2001; 108: 1299-1308
17. Blin O, Ferrandez AM, Pailhous J, Serratrice G. Dopa-sensitive and dopa-resistant gait parameters in Parkinson's disease. J Neurol Sci 1991; 103: 51-54
18. Morris ME, Iansek R, Matyas TA, Summers JJ. The pathogenesis of gait hypokinesia in Parkinson's disease. Brain 1994; 117 (Pt 5): 1169-1181
19. Morris ME, Iansek R, Matyas TA, Summers JJ. Ability to modulate walking cadence remains intact in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 1532-1534
20. Flyckt L, Sydow O, Bjerkenstedt L, Edman G, Rydin E, Wiesel FA. Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls. Psychiatry Res 1999; 86: 113-129
21. Fuller R, Nathaniel-James D, Jahanshahi M. Movement-related potentials prior to self-initiated movements are impaired in patients with schizophrenia and negative signs. Exp Brain Res 1999; 126: 545-555
22. Jahanshahi M, Frith CD. Willed action and its impairments. Cognitive Neuropsychol 1998; 15: 483-533